Pimecrolimus

FDA Approved: * December 27, 2018
Pharm Company: * ACTAVIS LABS UT INC
Category: Skin Care

* This drug may consist of multiple approval dates, manufacturers, or distributors. If applicable, they would be listed below under "NDC Database Records".



Pimecrolimus Overview

Pimecrolimus is an immunomodulating agent of the calcineurin inhibitor class used in the treatment of atopic dermatitis (eczema). It is available as a topical cream, once marketed by Novartis (however, Galderma has been promoting the compound in Canada since early 2007) under the trade name Elidel. Contents 1 Medical uses 2 Side effects 3 Pharmacology 4 References 5 External links Medical uses It has been proven to be effective in various inflammatory skin diseases, e.g., seborrheic ...

Read more Pimecrolimus Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Pimecrolimus

Recent Pimecrolimus Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Pimecrolimus
  • Cream: 1%
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

NDC Database Records for Pimecrolimus: (4 results)

Sorted by National Drug Code
  • 0591-2944 Pimecrolimus 10 mg/g Topical Cream by Actavis Pharma, Inc.
  • 68682-110 Pimecrolimus 10 mg/g Topical Cream by Oceanside Pharmaceuticals
  • 68682-111 Pimecrolimus 10 mg/g Topical Cream by Oceanside Pharmaceuticals
  • 68682-112 Pimecrolimus 10 mg/g Topical Cream by Oceanside Pharmaceuticals

Other drugs which contain Pimecrolimus or a similar ingredient: (1 result)




Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 October 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA